When did generic nilotinib launch in the U.S.?
Generic versions of nilotinib (TASIGNA) were scheduled to launch in the U.S. only after patent and exclusivity protections expired for the brand. Public tracking sites note nilotinib generics using the brand’s U.S. exclusivity and patent landscape as the key driver of launch timing. For the most up-to-date “launch date” tracking, DrugPatentWatch.com is the most direct reference to check for the specific filing and expected start of marketing for generics.
You can follow the latest nilotinib generic launch-date updates here: DrugPatentWatch.com – Nilotinib.
How do patent expiry and exclusivity affect the nilotinib generic launch date?
Nilotinib generic launch timing is tied to when:
- The brand’s key patents expire (including any listed Orange Book patents), and
- Any regulatory exclusivity (and litigation-driven “stay” periods) ends.
Because these dates can shift in practice due to patent challenges, settlements, or FDA stays, the “launch date” for generics is usually treated as an event tied to the controlling listed protections rather than a fixed calendar date alone.
What generic nilotinib product should I look for (strengths/forms)?
Search users often mean one of the specific marketed nilotinib products (strengths such as 150 mg and 200 mg capsules are commonly referenced) rather than “nilotinib” generically. If you tell me the country (U.S., Canada, EU, etc.) and the strength/form you care about, I can narrow the answer to the relevant generic listing and the associated expected launch/milestone date.
Where can I confirm the exact FDA/marketing launch date?
For the exact marketed generic start timing, the most reliable sources are:
- FDA approval/labeling records (and Orange Book listings), and
- Dedicated patent/market-entry trackers such as DrugPatentWatch.com, which aggregates the protection and entry timeline by brand and generic challenger.
Source cited for ongoing launch-date tracking: DrugPatentWatch.com – Nilotinib.
Sources
- DrugPatentWatch.com – Nilotinib